• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider King Debra

    6/4/25 4:42:25 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care
    Get the next $SYK alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    King Debra

    (Last) (First) (Middle)
    1941 STRYKER WAY

    (Street)
    PORTAGE MI 49002

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    05/27/2025
    3. Issuer Name and Ticker or Trading Symbol
    STRYKER CORP [ SYK ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    See Remarks
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    VP, Chief Digital and Information Officer. Exhibit 24, Power of Attorney, is attached.
    No securities are beneficially owned.
    /s/ Austin Y. Ke, attorney-in-fact for Debra King 06/04/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SYK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SYK

    DatePrice TargetRatingAnalyst
    2/26/2025$450.00Buy
    Citigroup
    12/2/2024$370.00 → $445.00Equal-Weight → Overweight
    Morgan Stanley
    9/10/2024$405.00Outperform
    Wolfe Research
    5/30/2024$372.00Neutral
    Goldman
    5/22/2024$392.00Hold → Buy
    Needham
    1/31/2024$315.00 → $360.00Hold → Buy
    Canaccord Genuity
    10/20/2023$345.00Buy
    ROTH MKM
    9/5/2023$310.00 → $315.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $SYK
    SEC Filings

    See more
    • SEC Form S-8 filed by Stryker Corporation

      S-8 - STRYKER CORP (0000310764) (Filer)

      5/30/25 4:16:27 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Stryker Corporation

      SD - STRYKER CORP (0000310764) (Filer)

      5/23/25 10:35:54 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - STRYKER CORP (0000310764) (Filer)

      5/13/25 5:29:41 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stryker receives FDA clearance for Incompass Total Ankle System

      Streamlining total ankle replacement with data-driven implants and surgical flexibility Stryker (NYSE:SYK), a global leader in medical technologies, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Incompass® Total Ankle System, an implant intended for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis. This new platform integrates the innovative technologies of Stryker's Inbone® and Infinity® systems into a single, comprehensive solution for total ankle replacement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625296275/en/Stryker's

      6/25/25 8:15:00 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker receives FDA clearance for OptaBlate® BVN Basivertebral Nerve Ablation System

      Stryker's first basivertebral nerve ablation system targets the basivertebral nerve to provide relief from chronic* vertebrogenic low back pain. PORTAGE, Mich., May 19, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced that its OptaBlate basivertebral nerve ablation system (OptaBlate BVN) received 510(k) clearance from the U.S. Food and Drug Administration. OptaBlate BVNA is used in a targeted minimally invasive procedure providing long-lasting† vertebrogenic pain relief1. The addition of the OptaBlate BVN to Stryker's pain portfolio expands its advanced pain therapy solutions for patients and is an intersection of its two core competencies: radiofre

      5/19/25 1:01:00 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker declares an $0.84 per share quarterly dividend

      Portage, Michigan, May 08, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable July 31, 2025, to shareholders of record at the close of business on June 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150

      5/8/25 8:00:00 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider King Debra

      3 - STRYKER CORP (0000310764) (Issuer)

      6/4/25 4:42:25 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Amendment: VP, Chief Accounting Officer Berry William E Jr covered exercise/tax liability with 1,005 shares, decreasing direct ownership by 28% to 2,643 units (SEC Form 4)

      4/A - STRYKER CORP (0000310764) (Issuer)

      5/23/25 7:43:32 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Amendment: VP, Chief Accounting Officer Berry William E Jr sold $211,370 worth of shares (755 units at $279.96), decreasing direct ownership by 29% to 1,853 units (SEC Form 4)

      4/A - STRYKER CORP (0000310764) (Issuer)

      5/23/25 7:39:38 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup resumed coverage on Stryker with a new price target

      Citigroup resumed coverage of Stryker with a rating of Buy and set a new price target of $450.00

      2/26/25 7:17:53 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Stryker from Equal-Weight to Overweight and set a new price target of $445.00 from $370.00 previously

      12/2/24 7:02:55 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Wolfe Research initiated coverage on Stryker with a new price target

      Wolfe Research initiated coverage of Stryker with a rating of Outperform and set a new price target of $405.00

      9/10/24 8:01:33 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care